Alembic Expands Strategic DifGen Tie-Up for US Complex Generics
Alembic Pharmaceuticals Ltd 路 Press Release 路 04 Nov 2026, 8:10 pm
Alembic Expands Strategic DifGen Tie-Up for US Complex Generics Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize a portfolio of 20+ differentiated complex generics in the US, targeting an aggregate reference market of ~$5 billion across injectable, transdermal, ophthalmic, and oral dosage forms. DifGen will manage development, regulatory, and US manufacturing, while Alembic will handle US commercialization and select manufacturing. The pipeline includes open First-to-File (FTF) assets and potential Day-1 launches with limited competition. Initial commercial launches are slated to commence from FY28, granting Alembic reserved US manufacturing capacity.
Original exchange filing (PDF)
More announcements from Alembic Pharmaceuticals Ltd
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Binimetinib Tablets, 15 mg and 45 mg. 路 15 Nov 2026
- Please find attached herewith the Transcript of Post Results Conference Call held on 4th November, 2026. 路 10 Nov 2026
- Alembic Pharmaceuticals Limited receives USFDA Final Approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). 路 05 Nov 2026
- Please find attached Audio Recording of Investor Call. 路 05 Nov 2026
- Please find attached intimation under Regulation 30(5) of SEBI (LODR) Regulations, 2015. 路 04 Nov 2026
- Please find attached Investor Presentation for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Press Release for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
- Please find attached Unaudited Financial Results for the Quarter and Half Year Ended September 30, 2026. 路 04 Nov 2026
